Extensive investigations of mitochondrial DNA genome in treated HIV-Lnfected subjects beyond mitochondrial DNA depletion

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 2, 2005, Pages 181-188

  McComsey, Grace ^a   Bai, Ren Kui ^b,d   Jen Fue, Maa ^c   Seekins, Daniel ^c   Wong, Lee Jun ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Lipoatrophy; Lipodystrophy; Mitochondrial DNA; Mitochondrial toxicity

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HYDROXYUREA; INDINAVIR; LACTIC ACID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DNA PRIMERS; DNA, MITOCHONDRIAL; FEMALE; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, TRANSFER, LEU; RNA, VIRAL; VIRAL LOAD;

EID: 19644363034     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
2. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
3. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38:2743-2749.
4. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA. in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337:508-510.
5. McComsey GA, Paulsen DM, Lonergan TJ, et al. Improvements in lipoatrophy, mitochondrial DNA content and adipose tissue apoptosis levels after replacement of stavudine with either abacavir or zidovudine. AIDS. 2005;19:15-23.
6. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329-1338.
7. McComsey G, Tan D-J, Lederman MM, et al. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS. 2002;16:513-518.
8. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol. 2003;70:497-505.
9. Cossarizza A, Pinti M, Moretti L, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis. 2002;185:299-305.
10. Henry K, Erice A, Balfour HH, et al. Lymphocyte mitochondrial biomarkers in asymptomatic HIV-1-infected individuals treated with nucleoside reverse transcriptase inhibitors. AIDS. 2002;16:2485-2487.
11. Miro O, Lopez S, Pedrol E, et al, Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther. 2003;8:333-338.
12. ACTG recommendations for lactate blood collection. Available at: http://aactg.s-3.com. Accessed March 30, 2005.
13. Lahiri D, Nurnberger J, Jr, A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.
14. Chen TJ, Boles RG, Wong L. Detection of mitochondrial DNA mutations by temporal temperature gradient gel electrophoresis. Clin Chem. 1999; 45:1162-1167.
15. Wong LJ, Liang MH, Kwon H, et al. Comprehensive scanning of the entire mitochondrial genome for mutations. Clin Chem. 2002;48: 1901-1912.
16. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside analogue reverse transcriptase inhibitors. Am J Hum Genet. 2003;72:549-560.
17. Hoy JF, Gahan ME, Carr A, et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis. 2004;190: 688-692.
18. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
19. Gallant JE, Staszewski S. Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
20. Lund KC, Wallace KB. Mitochondrial toxicity of 3′-azido- 3′deoxythymidine (AZT) in the absence of mitochondrial DNA (mtDNA) depletion [abstract]. Presented at: Mitochondrial Medicine 2004 Meeting; 2004; Pittsburgh.
21. Oldfors A, Holme E, Tulinius M, et al. Tissue distribution and disease manifestations of the tRNA(Lys) A→G(8344) mitochondrial DNA mutation in a case of myoclonus epilepsy and ragged red fibres. Acta Neuropathol (Berl). 1995;90:328-333.
22. Mancuso M, Filosto M, Tsujino S, et al. Muscle glycogenosis and mitochondrial hepatopathy in an infant with mutations in both the myophosphorylase and deoxyguanosine kinase genes. Arch Neurol. 2003; 60:1445-1447.
23. Vu TH, Tanji K, Pallotti F, et al. Analysis of mtDNA deletions in muscle by in situ hybridization. Muscle Nerve. 2000;23:80-85.
24. Clark KM, Taylor RW, Johnson MA, et al. An mtDNA mutation in the initiation codon of the cytochrome C oxidase subunit II gene results in lower levels of the protein and a mitochondrial encephalomyopathy. Am J Hum Genet. 1999;64:1330-1339.
25. Bai RK, Perng CL, Hsu CH, et al. Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease. Ann NY Acad Sci. 2004;1011:304-309.
26. Wong LJ, Pemg CL, Hsu CH, et al. Compensatory amplification of mtDNA in a patient with a novel deletion/duplication and high mutant load. J Med Genet. 2003;40:e125.
27. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associatcd lipodystrophy in an ambulatory population. AIDS. 2001; 15:1389-1398.
28. McComsey G, Maa J. Host factors may be more important than the choice of antiretrovirals in the development of lipoatrophy. AIDS Read, 2003;13: 539-559.
29. Cherry CL, Gahan ME, McArthur JC, et al. Exposure to dideoxynucleotides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr. 2002;30:271-277.
30. Nolan D, Hammond E, James I, et al. Contribution of nucleoside analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther. 2003;8:617-626.